Cite
HARVARD Citation
Tapete, G. et al. (2022). Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Inflammatory bowel diseases. 28 (1), pp. 62-69. [Online].